Reviewed by Michael Gill, B. Sc.
25 Neurofeedback Clinical Trials Near Me
Top Cities for Neurofeedback Clinical Trials
Image of New Haven in Connecticut.
New Haven
3Active Trials
Yale University School of MedicineTop Active Site
Image of Tulsa in Oklahoma.
3Active Trials
Hardesty Center for Clinical Research and NeuroscienceTop Active Site
Most Recent Neurofeedback Clinical Trials

Neurofeedback therapy is one of the most promising new medical technologies. Although the field is still young, research is emerging that backs up what professionals have known for years.

What Are Neurofeedback Clinical Trials?

Neurofeedback gives real-time feedback on neurophysiological signals, modulating pain-related brain activity. Many clinical trials seek to evaluate the effectiveness of neurofeedback therapy for chronic pain patients.

Why Is Neurofeedback Being Studied In Clinical Trials?

Using neurofeedback to treat chronic pain is unique, but the evidence for its effectiveness is encouraging. If we want to find the best effective method of providing neurofeedback, we need more rigorous studies comparing different protocols.

There is a link between how the brain works and how a person acts. The brain responds to behavioral changes, and behavioral changes can affect the brain. Attention deficit hyperactivity disorder (ADHD), for example, has been linked to certain patterns of brain activity, most notably in the prefrontal cortex. Psyche, actions, and education all intersect here somehow.

The goal of neurofeedback is to bring about behavioral changes by way of neural retraining.

How Does Neurofeedback Treatment Work?

Before each treatment session, the patient reports any changes in their symptoms so the doctor can monitor their progress. Neurofeedback treatment focuses on the central nervous system and works to improve the way the brain regulates itself.


The patient will have electrodes connected to an electroencephalograph (EEG) machine that is placed on their head at the beginning of each session. These are used to gauge mental performance. There is no set number of electrodes used because that is determined by the therapist and the treatment being administered.

At the start of the session, a live display of the individual's brain waves appears. The practitioner gives the patient a set of instructions designed to cause a change in the subject's brainwave pattern. A video game or other stimulus may be used to get the brain working in new ways to process information. Sounds like music, a single tone, or a series of abrupt pauses and resumes are often used.

The EEG will provide real-time feedback on how the stimuli disrupt, alter, or heighten brain activity as the brain reacts to them. Brain activity may fluctuate significantly from one session to the next, as measured by the readings. Because no electricity flows through them, participants feel no pain from the electrodes. The sole purpose is to monitor mental activity.

Neurofeedback Therapy: The Top Benefits

Neurofeedback therapy can be very helpful for a wide range of mental health problems, but is most effective in treating:

  • PTSD and Symptoms of Traumatic Brain Injury (TBI)
  • Depressive episodes
  • ADHD

Who Are The Key Opinion Leaders On Neurofeedback Clinical Trial Research?

Vincent Monastra, PHD - demonstrated at the FPI Attention Disorders Clinic in New York that, In treating attention deficit hyperactivity disorder (ADHD), neurofeedback training may prove more effective than the currently used medication, Methylphenidate/Ritalin.

Naomi J. Steiner, MD - and associates at Tufts Medical Center have shown Neurofeedback is a promising ADHD treatment.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 14th, 2021

Last Reviewed: November 1st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57. Review. Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther. 1995 Mar;33(3):335-43. Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation. J Trauma Stress. 2015 Dec;28(6):489-98. doi: 10.1002/jts.22059. Epub 2015 Nov 25. Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG, Keane TM, Marx BP. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychol Assess. 2018 Mar;30(3):383-395. doi: 10.1037/pas0000486. Epub 2017 May 11. Bernstein DP, Stein JA, Newcomb MD, Walker E, Pogge D, Ahluvalia T, Stokes J, Handelsman L, Medrano M, Desmond D, Zule W. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abuse Negl. 2003 Feb;27(2):169-90. Diamond A. Executive functions. Annu Rev Psychol. 2013;64:135-68. doi: 10.1146/annurev-psych-113011-143750. Epub 2012 Sep 27. Review. Diamond A. Executive functions. Annu Rev Psychol. 2013;64:135-68. doi: 10.1146/annurev-psych-113011-143750. Epub 2012 Sep 27. Review. Sitaram R, Ros T, Stoeckel L, Haller S, Scharnowski F, Lewis-Peacock J, Weiskopf N, Blefari ML, Rana M, Oblak E, Birbaumer N, Sulzer J. Closed-loop brain training: the science of neurofeedback. Nat Rev Neurosci. 2017 Feb;18(2):86-100. doi: 10.1038/nrn.2016.164. Epub 2016 Dec 22. Review. Erratum in: Nat Rev Neurosci. 2019 May;20(5):314. Mehling WE, Price C, Daubenmier JJ, Acree M, Bartmess E, Stewart A. The Multidimensional Assessment of Interoceptive Awareness (MAIA). PLoS One. 2012;7(11):e48230. doi: 10.1371/journal.pone.0048230. Epub 2012 Nov 1. Briere J, Weathers FW, Runtz M. Is dissociation a multidimensional construct? Data from the Multiscale Dissociation Inventory. J Trauma Stress. 2005 Jun;18(3):221-31.